peptide cocktail-pulsed dendritic cells

Peptide cocktail-pulsed dendritic cells are a form of personalized cell-based immunotherapy where dendritic cells (DCs), potent antigen-presenting cells, are cultured ex vivo and loaded with a pool (cocktail) of synthetic peptides derived from tumor-associated antigens specific to a patient's cancer[1][2]. These antigen-loaded DCs are matured and subsequently infused back into the patient, either alone or in combination with other immune cells such as cytotoxic T lymphocytes (CTLs), with the intent to stimulate a broad and potent antigen-specific T cell immune response targeting cancer cells[1][2]. The approach allows for tailored therapy addressing unique tumor antigens or neoantigens present in the patient's tumor. The key *mechanism of action* is the activation of both CD4+ helper T cells and CD8+ cytotoxic T cells through antigen presentation on MHC class I and II molecules, leading to a systemic anti-tumor immune response[1][2][4][5]. This therapy is being explored in a variety of solid tumors, and preliminary studies show promising safety and immunogenicity outcomes[1][2].

Other names

multiple peptide-pulsed dendritic cellsmultiple peptides-pulsed dendritic cell vaccinepeptide-pulsed dendritic cells